Report
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
Report documents
-
Extract of the final report
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
-
Final report
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
-
Documentation of comments on the preliminary report
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
-
Preliminary report
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
-
Report plan version 1.0
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
-
Documentation and evaluation of comments on the preliminary report plan
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
-
Preliminary report plan
Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis
Press releases
Biologics in rheumatoid arthritis: better evidence, but direct comparisons still lacking
Only few differences between biologics detectable / Operationalization of outcomes can influence results
Project details
- Project no.
- A16-70
- Commission
- Commission awarded on 24.11.2016 by the Federal Joint Committee (GBA).
- Report type
- Report
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints